Compare DexCom, Inc. (DXCM) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Matson Inc — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while Matson Inc trades at $225.53 (market cap $6.81B). The key difference: DexCom, Inc. is far larger — about 4.7× Matson Inc's market cap, and Matson Inc pays a 0.67% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Matson Inc for 23 Days on average.
| DXCM | MATX | |
|---|---|---|
Market Cap | $31.86B | $6.81B |
Volume | 3,607,070 | 255,080 |
Sector | Health | Industrials |
52-Week High | $92.34 | $238.60 |
52-Week Low | $54.84 | $88.05 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $31.32B | $7.41B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Matson (MATX) trades at $224.80, up 0.84% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong Q2 2026 earnings of $4.27 per share, beating estimates, and raised its full-year outlook. Revenue growth is steady, with 2026 revenue projected at $3.5 billion and net profit at $464 million, supported by a robust net income margin of 13.41%.
The outlook for MATX is positive, driven by earnings beats, cost controls, and institutional accumulation. Key risks include exposure to freight demand cycles and competitive pressures. Wall Street consensus is bullish, with 8 of 12 analysts rating it a Buy and an implied 27.33% upside potential, though investors should monitor macroeconomic trends affecting transportation stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
